Non covalent BTKis ruling CLL again #pirtobrutinib #nemtabrutinib!Continued impressive waterfall plot with Pirtobrutinib incl. post BTKi-BCL2, del 17p,independent of C481Sm w/ Rx discontinuation rate <1% Cant get better than this!Excellent talks by anthony-mato& Dr.JenniferWoyach

"Add on" U2 in pts w/detectable MRD while on ibrutinib➡️MRD-guided discontinuation. 77% achieving uMRD, 1st as early as ~7m, unchanged AE profile,v high PFS. Another potential time limited therapy in #CLL; saves venetoclax for later. Outstanding presentation by Lindsey Roeker #ASH21

#DLBCL landscape in a GIF (sic) #Bispecifics to appear here next? #ASH21

Mind officially blown🤯🤯 This opens so many lines of investigation! Could CHIP be an evolutionary mechanism to prevent AD like #SCD for malaria? since AD is more common in Caucasians, interested to know CHIP incidence in other populations! David Steensma, MD Swapna Thota MD

RCHOP may fare as good as higher intensity regimens in #HGBCL-NOS, excl. Burkitt and DHL Key data in an understudied population. Great analysis and alluvial plot illustration by Adam Zayac and grateful for the collaboration !

#TCL updates #ASH21 #lymsm Abs 620 Lysa Lymphoma : BV+benda in R/R TCL Retrospective, n=82 Benda mono: ORR 50% PFS 3.6 mo BV mono in ALCL: ORR 86% CR 57% PFS 13.3 mo CD30+ 63%, 50% refractory B2: ORR 70%, CR 51% PFS 8.3 mo OS 26.3 mo Utility in our practice Paola Ghione MD, MSEpi?

It is all about EFS definitions...? ZUMA-7, TRANSFORM, BELINDA. #ASH21

Dr Kanti Rai once said “… no one is an expert in CLL. I have been studying this disease for decades, and still too many of my patients die. If I were truly an expert, the disease would have been cured by now.” thank you for reminding us David Steensma, MD ascopubs.org/doi/full/10.12…

After arriving in Buffalo, NY in 1883, Dr. Roswell Park began to focus more intently on the mystery of cancer. Read the story of the world’s first cancer research center (Roswell Park) cancerhistoryproject.com/institutions/i…

We look forward to hearing about #AML from Eunice Wang, MD. Jan. 13. roswellpark.org/eunice-wang Roswell Park Icahn School of Medicine at Mount Sinai

Calling all folks who treat patients with lymphoma! Please fill out our survey about how you use polatuzumab vedotin in your clinical practice, as part of a new IRB-approved study: redcap.link/cekd9rqy #lymsm #onctwitter #hemetwitter

Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial ashpublications.org/blood/article/… Congratulations Matthew Frigault and team who took impressively good care of our patients.

Ofatumumab- HyperCVAD in MCL This paper has been in making for many years and am proud to announce that its finally out in #CancerJournal. O-HyperCVAD induced 96% MRD negativity by flow post induction but PFS and OS only 46 mo and 56 mo still acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

I’m tired of my job! Work is not fun anymore! ‘Should I stay or should I go?’ Join usama durani Mayo Clinic and me Roswell Park as we chat about 👉 pros/cons 👉strategies for success Session: Junior Faculty Career Development #ASH22 Time: 4.30-5.45pm Monday (we start at 5 pm)

Shout out to my fellow LSRMP colleague Arushi Khurana analysis of BCL6-R outcomes in the LEO consortium BCL-6 DHL outcomes are more comparable to DLBCL NOS than BCL 2 R #ASH23

Simplify geriatric assessments! Easy to administer “Timed up and go” as an objective measure of frailty and predictor of severe therapy related toxicity in DLBCL. Outstanding work by ⁦⁦Pallawi Torka⁩ #lymsm #ASH23

Sworder et al MRD detection in DLBCL using PhasED-Seq Ct-DNA-MRD predicts outcomes when discordant with PET: Outcomes for CT-DNA+, PET - worse than CTDNA-PET+. Need to overcomes barriers for its use to treat & consolidate in RW practice #ASH23

Another ctDNA study suggesting greater predictive value over PET. Mark Roschewski EOT response post 1L in DLBCL, Landmark comparison of EOT PET vs ctDNA. Undetectable ctDNA by PhasED-sea at EOT predicts a very low likelihood of progression potentially sparing more biopsies/imaging

Useful data by Dr.Lacoboni: Prior Benda exposure did NOT impact CRS,toxicities, survival w/BsAb therapy in DLBCL&FL. More pts w/shorter washout b4 BsAb needed to explore the impact of more recent Benda exposure on outcomes,(small# DLBCL pts with Benda use within 6m had lower PFS)

Excellent Junior Faculty career development session on now at #ASH23 Dr. Oyebimpe Adesina and Dr. Cassandra Josephson sharing their journey on securing and staying funded as junior faculty. Great tips and many take-aways! “Persistence is key” #lymsm